Archive \ Volume.13 2022 Issue 1

Common Sensitive Prognostic Marker in Breast Cancer and their Clinical Significance: A Review Article

Ahmed Fawzy , Yaser Abdulsalam Alqelaiti , Mohammed Mubrik Almatrafi , Omar Mohammad Almatrafi , Elaaf Abdulsalam Alqelaiti

The most common cancer in women is breast cancer. Also, it is the biggest cause of death in women with cancer. The exact cause is not known but there are risk factors such as women above 55, Caucasian races, late age of first pregnancy, genetic factors and, family history. It has two classifications histological and molecular. Tumor biomarkers are either prognostic markers or predictive markers. We here present a review for breast cancer prognostic markers. Breast cancer prognostic markers are divided into classical (ER. PR, Ki67, and HER2) and novel (P53, cyclin E, cyclin D1, BRCA 1-2, VEGF, and TBX 2-3). The objective of this review is to evaluate the important prognostic marker for breast cancer and to provide its clinical significance.

The use of biomarkers helps breast cancer patients to get the best treatment. The prognostic markers are to evaluate the outcome. They either indicate for good prognosis as ER and PR or indicate for bad prognosis as P53, HER2, cyclin E, cyclin D1, BRCA1, BRCA2, VEGF, TBX2, and TBX3. Also, some can be used as an important indicator for tumor recurrence as ER, Ki67, P53, and cyclin E. Tumor prognostic markers are clinically important for breast cancer patients. We recommend its clinical use to help breast cancer patients get the best treatment and prognosis options.

How to cite:
Fawzy A, Alqelaiti Y A, Almatrafi M M, Almatrafi O M, Alqelaiti E A. Common Sensitive Prognostic Marker in Breast Cancer and their Clinical Significance: A Review Article. Arch. Pharm. Pract. 2022;13(1):40-5.
Fawzy, A., Alqelaiti, Y. A., Almatrafi, M. M., Almatrafi, O. M., & Alqelaiti, E. A. (2022). Common Sensitive Prognostic Marker in Breast Cancer and their Clinical Significance: A Review Article. Archives Of Pharmacy Practice, 13(1),40-45.

Download Citation

1.        World health organization WHO [internet]. [cited 2018 Feb 10]. Available from:

2.        Al-Shahrani Z, Al-Rawaji A, Al-Madouj AN, Hayder MS, Al-Zahrani A, Al-Mutlaq H, et al. Cancer Incidence Report Saudi Arabia 2014. Saudi Cancer Regist. 2017:1-81. Available from:

3.        Saggu S, Rehman H, Abbas ZK, Ansari AA. Recent incidence and descriptive epidemiological survey of breast cancer in Saudi Arabia. Saudi Med J. 2015;36(10):1176-80.

4.        John Hopkins medicine [Internet]. [cited 2018 Feb 10]. Available from:,P00160

5.        McPhearson K, Steel C, Dixon J. Breast cancer-epidemiology, risk factors and genetics. Brit Med J. 2000;321(7261):624-8.

6.        Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002;13(8):741-51.

7.        Rafnsson V, Tulinius H, Jónasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control. 2001;12(2):95-101.

8.        Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216(2):141-50.

9.        Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929-43.

10.      American Cancer Society [Internet]. [update 2017 December 20; cited 2018 Feb 10]. Available from:

11.      American Cancer Society [Internet]. [update 2017 September 22; cited 2018 Feb 10]. Available from:

12.      Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v8-v30.

13.      Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2010;2(2):125-48.

14.      Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Elizabeth AF, et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol. 2010;4:15-34.

15.      Kurdi L, Alhusayni F. Cytotoxicity effect of 5-fluorouracil and bee products on the MCF-7 Human Breast Cancer Cell Line in vitro. Int J Pharm Phytopharmacol Res. 2020;10(2):19-26.

16.      Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017;3(1):5-11.

17.      Kabel AM, Elkhoely AA. Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer. Tissue Cell. 2016;48(2):89-95.

18.      Lumachi F, Brunello A, Maruzzo M, Basso U, Mm Basso S. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20(5):596-604.

19.      Han HH, Lee SH, Kim BG, Lee JH, Kang S, Cho NH. Estrogen receptor status predicts late-onset skeletal recurrence in breast cancer patients. Medicine. 2016;95(8).

20.      Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284-98.

21.      Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, et al. Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15(1):138.

22.      Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, et al. Outcomes of estrogen receptor negative and progesterone receptor positive breast cancer. PloS one. 2015;10(7):e0132449.

23.      Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol. 2012;357(1-2):18-29.

24.      Giulianelli S, Molinolo A, Lanari C. Targeting progesterone receptors in breast cancer. Vitam Horm. 2013;93:161-84.

25.      Lanari C, Wargon V, Rojas P, Molinolo AA. Antiprogestins in breast cancer treatment: are we ready?. Endocr Relat Cancer. 2012;19(3):R35-50.

26.      Brown DC, Gatter KC. Ki67 protein: the immaculate deception?. Histopathology. 2002;40(1):2-11.

27.      Mohamed AA, Obaid NE, Abdelghani S, Alfahed A, Waggiallah HA, Eltayeb LB. Immunohistochemical expression of survivin and KI-67 as tumor markers in breast cancer infected females: A cross-sectional study. Pharmacophore. 2020;10(5):41-5.

28.      Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477-91.

29.      Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21(2):100-7.

30.      Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111-28.

31.      Kabel AM. Tumor protein p53: Novel aspects of an old tumor marker. J Cancer Res Ther. 2015;3(2):25-7.

32.      Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy. Front Oncol. 2015;5:288.

33.      Trovesi C, Manfrini N, Falcettoni M, Longhese MP. Regulation of the DNA damage response by cyclin-dependent kinases. J Mol Biol. 2013;425(23):4756-66.

34.      Bi H, Li S, Qu X, Wang M, Bai X, Xu Z, et al. DEC1 regulates breast cancer cell proliferation by stabilizing cyclin E protein and delays the progression of cell cycle S phase. Cell Death Dis. 2015;6(9):e1891.

35.      Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(43):70113-27.

36.      Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Mol Biol Rep. 2012;39(3):2109-18.

37.      Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1).

38.      Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016;53(7):465-71.

39.      Huzarski T, Byrski T, Gronwald J, Górski B, Domagała P, Cybulski C, et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. 2013;31(26):3191-6.

40.      Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, et al. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res Treat. 2013;140(2):375-84.

41.      Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, et al. Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: a systematic review and meta-regression. PloS One. 2016;11(5):e0154789.

42.      Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One. 2013;8(2):e55309.

43.      Shivakumar S, Prabhakar BT, Jayashree K, Rajan MG, Salimath BP. Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol. 2009;135(4):627-36.

44.      Lv Y, Si M, Chen N, Li Y, Ma X, Yang H, et al. TBX2 over-expression promotes nasopharyngeal cancer cell proliferation and invasion. Oncotarget. 2017;8(32):52699-707.